MARKET

LIFE

LIFE

Atyr Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.830
+0.080
+2.91%
Closed 16:00 06/30 EDT
OPEN
2.750
PREV CLOSE
2.750
HIGH
2.869
LOW
2.750
VOLUME
69.81K
TURNOVER
120.15K
52 WEEK HIGH
13.10
52 WEEK LOW
2.600
MARKET CAP
79.40M
P/E (TTM)
-1.5633
1D
5D
1M
3M
1Y
5Y
Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year
Quite a few insiders have dramatically grown their holdings in aTyr Pharma, Inc. ( NASDAQ:LIFE ) over the past 12...
Simply Wall St. · 06/24 18:22
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and cancer. SAN DIEGO...
GlobeNewswire · 06/14 12:00
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
Conference hosted by The Ohio State University’s Center for RNA Biology to showcase latest advancements in tRNA biology SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and de...
GlobeNewswire · 06/13 12:00
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S. ...
GlobeNewswire · 06/01 12:00
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 05/23 16:12
aTyr Pharma stock dips after Piper Sandler cuts price target on lung disease drug approval timeline
aTyr Pharma (NASDAQ:LIFE) stock fell ~3% after Piper Sandler lowered its target on the company's shares to $11 from $19. Piper Sandler analyst maintained an Overweight rating on the stock
Seekingalpha · 05/18 15:11
Piper Sandler Adjusts ATyr Pharma's Price Target to $11 From $19, Reiterates Overweight Rating
MT Newswires · 05/18 05:39
aTyr Pharma Presents Clinical Data For Efzofitimod (ATYR1923) At The American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod
Benzinga · 05/17 12:11
More
No Data
Learn about the latest financial forecast of LIFE. Analyze the recent business situations of Atyr Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LIFE stock price target is 17.17 with a high estimate of 21.00 and a low estimate of 11.00.
High21.00
Average17.17
Low11.00
Current 2.850
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 56
Institutional Holdings: 20.40M
% Owned: 72.70%
Shares Outstanding: 28.06M
TypeInstitutionsShares
Increased
13
456.80K
New
6
68.73K
Decreased
12
827.00K
Sold Out
12
625.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.93%
Key Executives
Non-Executive Chairman/Independent Director
John Clarke
President/Chief Executive Officer/Director
Sanjay Shukla
Chief Financial Officer
Jill Broadfoot
General Counsel/Secretary
Nancy Denyes
Director
Sara Zaknoen
Independent Director
Timothy Coughlin
Independent Director
Jane Gross
Independent Director
Svetlana Lucas
Independent Director
Paul Schimmel
No Data
No Data
About LIFE
aTyr Pharma Inc is a biotechnology company. The Company’s programs include ATYR1923, ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. It is developing ATYR1923 as a disease-modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need, which include interstitial lung disease (ILD), a group of rare immune-mediated disorders that can cause progressive fibrosis of the lung. ATYR2810, is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands, VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive solid tumors where NRP2 is implicated. The Company is also advancing its preclinical pipeline of tRNA synthetases and NRP2 targeting antibodies through internal research efforts and academic collaborations.

Webull offers kinds of aTyr Pharma Inc stock information, including NASDAQ:LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.